Daniel A Harki (Daniel Harki)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 35

Top Venues

ACS medicinal chemistry letters

Journal of medicinal chemistry

bioRxiv : the preprint server for biology

RSC advances

University of Minnesota, Twin Cities

Pennsylvania State University University Park (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Minnesota, Twin Cities

United States

Assistant Professor :: Department of Medicinal Chemistry

California Institute of Technology

United States

Post-doctoral Scholar :: Division of Chemistry and Chemical Engineering

Education History

Pennsylvania State University University Park

United States

PHD :: Department of Chemistry

Publications

Katherine F M Jones, Özlem Demir, Mackenzie K Wyllie, Michael J Grillo, Clare Morris, Sophia P Hirakis, Rahul Dadabhau Kardile, Michael A Walters, Reuben S Harris, Rommie Elizabeth Amaro, Daniel A Harki
Development of Allosteric Small Molecule APOBEC3B Inhibitors from In Silico Screening. bioRxiv : the preprint server for biology (2024)
Samantha A Kennelly, Jacob M Sawyer, Anne F Payne, Alexander T Ciota, Daniel A Harki
Development of 3'-Deoxy-3',4'-didehydro-nucleoside Prodrug Inhibitors of West Nile and Zika Viruses. ACS medicinal chemistry letters 15 (8) (2024)
Samantha A Kennelly, Jacob M Sawyer, Anne F Payne, Alexander T Ciota, Daniel A Harki
Development of 3'-Deoxy-3',4'-didehydro-nucleoside Prodrug Inhibitors of West Nile and Zika Viruses. ACS medicinal chemistry letters 15 (8) (2024)
Katherine F M Jones, Özlem Demir, Mackenzie K Wyllie, Michael J Grillo, Clare Morris, Sophia P Hirakis, Rahul Dadabhau Kardile, Michael A Walters, Reuben S Harris, Rommie Elizabeth Amaro, Daniel A Harki
Development of Allosteric Small Molecule APOBEC3B Inhibitors from In Silico Screening. bioRxiv : the preprint server for biology (2024)
Samantha A Kennelly, Jacob M Sawyer, Anne F Payne, Alexander T Ciota, Daniel A Harki
Development of 3'-Deoxy-3',4'-didehydro-nucleoside Prodrug Inhibitors of West Nile and Zika Viruses. ACS medicinal chemistry letters 15 (8) (2024)
Caroline R Buchholz, Molly S Sneddon, Joseph E McPherson, Sourav Das, Clifford T Gee, Michael J Grillo, Sergio C Chai, Richard E Lee, Taosheng Chen, Daniel A Harki, Anang A Shelat, William C K Pomerantz
Fragment-Based NMR Screening of the BPTF PHD Finger Methyl Lysine Reader Leads to the First Small-Molecule Inhibitors. ACS medicinal chemistry letters 14 (10) (2023)
Jacob M Sawyer, Kellan T Passow, Daniel A Harki
Synthesis and photophysical characterization of fluorescent indole nucleoside analogues. RSC advances 13 (24) (2023)
Katherine F M Jones, Mohamed Shehata, Michael A Carpenter, Rommie Elizabeth Amaro, Daniel A Harki
APOBEC3A Catalytic Inactivity Mutation Induces Tertiary Structure Destabilization. ACS medicinal chemistry letters 14 (3) (2023)
Erik B Faber, Luxin Sun, Jian Tang, Emily R Roberts, Sornakala Ganeshkumar, Nan Wang, Damien M Rasmussen, Abir Majumdar, Laura E Hirsch, Kristen John, An Yang, Hira Khalid, Jon E Hawkinson, Nicholas M Levinson, Vargheese M Chennthukuzhi, Daniel A Harki, Ernst K Schonbrunn, Gunda I Georg
Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding. Nature communications 14 (1) (2023)
Jared J Anderson, Michael J Grillo, Daniel A Harki
Development of Allosteric NIK Ligands from Fragment-Based NMR Screening. ACS medicinal chemistry letters 14 (12) (2023)
Anand Divakaran, Daniel A Harki, William C K Pomerantz
Recent progress and structural analyses of domain-selective BET inhibitors. Medicinal research reviews (2023)
Jared J Anderson, Michael J Grillo, Daniel A Harki
Development of Allosteric NIK Ligands from Fragment-Based NMR Screening. ACS medicinal chemistry letters 14 (12) (2023)
Seyed Arad Moghadasi, Rayhan G Biswas, Daniel A Harki, Reuben Stewart Harris
Rapid resistance profiling of SARS-CoV-2 protease inhibitors. bioRxiv : the preprint server for biology (2023)
Jared J Anderson, Michael J Grillo, Daniel A Harki
Development of Allosteric NIK Ligands from Fragment-Based NMR Screening. ACS medicinal chemistry letters 14 (12) (2023)
Seyed Arad Moghadasi, Rayhan G Biswas, Daniel A Harki, Reuben Stewart Harris
Rapid resistance profiling of SARS-CoV-2 protease inhibitors. bioRxiv : the preprint server for biology (2023)
Reuben Stewart Harris, Seyed Moghadasi, Rayhan G Biswas, Daniel A Harki
Rapid resistance profiling of SARS-CoV-2 protease inhibitors. Research square (2023)
Samantha A Kennelly, Ramkumar Moorthy, Ruben Silva Otero, Daniel A Harki
Expanding Catch and Release DNA Decoy (CRDD) Technology with Pyrimidine Mimics. Chemistry (Weinheim an der Bergstrasse, Germany) 28 (58) (2022)
Huarui Cui, Anand Divakaran, Zachariah J Hoell, Mikael O Ellingson, Cole R Scholtz, Huda Zahid, Jorden A Johnson, Elizabeth C Griffith, Clifford T Gee, Amani L Lee, Shalil Khanal, Ke Shi, Hideki Aihara, Vijay H Shah, Richard E Lee, Daniel A Harki, William C K Pomerantz
A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes. Journal of medicinal chemistry 65 (3) (2022)
Nicholas H Moeller, Kellan T Passow, Daniel A Harki, Hideki Aihara
SARS-CoV-2 nsp14 Exoribonuclease Removes the Natural Antiviral 3'-Deoxy-3',4'-didehydro-cytidine Nucleotide from RNA. Viruses 14 (8) (2022)
Anand Divakaran, Cole R Scholtz, Huda Zahid, Wenwei Lin, Elizabeth C Griffith, Richard E Lee, Taosheng Chen, Daniel A Harki, William C K Pomerantz
Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. ACS medicinal chemistry letters 13 (10) (2022)
Ke Shi, Nicholas H Moeller, Surajit Banerjee, Jennifer L McCann, Michael A Carpenter, Lulu Yin, Ramkumar Moorthy, Kayo Orellana, Daniel A Harki, Reuben Stewart Harris, Hideki Aihara
Structural basis for recognition of distinct deaminated DNA lesions by endonuclease Q. Proceedings of the National Academy of Sciences of the United States of America 118 (10) (2021)
Ramkumar Moorthy, Samantha A Kennelly, Deborah J Rodriguez, Daniel A Harki
An efficient synthesis of RNA containing GS-441524: the nucleoside precursor of remdesivir. RSC advances 11 (50) (2021)
Kellan T Passow, Haley S Caldwell, Kiet A Ngo, Jamie J Arnold, Nicole M Antczak, Anoop Narayanan, Joyce Jose, Shana J Sturla, Craig E Cameron, Alexander T Ciota, Daniel A Harki
A Chemical Strategy for Intracellular Arming of an Endogenous Broad-Spectrum Antiviral Nucleotide. Journal of medicinal chemistry 64 (20) (2021)
Huarui Cui, Angela S Carlson, Mary A Schleiff, Anand Divakaran, Jorden A Johnson, Caroline R Buchholz, Huda Zahid, Nora R Vail, Ke Shi, Hideki Aihara, Daniel A Harki, Grover P Miller, Joseph J Topczewski, William C K Pomerantz
4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. Journal of medicinal chemistry 64 (14) (2021)
Paul A Jackson, Henry A M Schares, Katherine F M Jones, John C Widen, Daniel P Dempe, Francois Grillet, Matthew E Cuellar, Michael A Walters, Daniel A Harki, Kay M Brummond
Synthesis of Guaianolide Analogues with a Tunable α-Methylene-γ-lactam Electrophile and Correlating Bioactivity with Thiol Reactivity. Journal of medicinal chemistry 63 (23) (2020)
Huarui Cui, Anand Divakaran, Anil K Pandey, Jorden A Johnson, Huda Zahid, Zachariah J Hoell, Mikael O Ellingson, Ke Shi, Hideki Aihara, Daniel A Harki, William C K Pomerantz
Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*. Angewandte Chemie (International ed. in English) 60 (3) (2020)
Maksim V Kvach, Fareeda M Barzak, Stefan Harjes, Henry A M Schares, Harikrishnan M Kurup, Katherine F Jones, Lorraine Sutton, John Donahue, Richard T D'Aquila, Geoffrey B Jameson, Daniel A Harki, Kurt L Krause, Elena Harjes, Vyacheslav V Filichev
Differential Inhibition of APOBEC3 DNA-Mutator Isozymes by Fluoro- and Non-Fluoro-Substituted 2'-Deoxyzebularine Embedded in Single-Stranded DNA. Chembiochem : a European journal of chemical biology 21 (7) (2019)
Kellan T Passow, Daniel A Harki
4-Cyanoindole-2'-deoxyribonucleoside (4CIN): A Universal Fluorescent Nucleoside Analogue. Organic letters 20 (14) (2018)
Jordan A Naumann, John C Widen, Leslie A Jonart, Maryam Ebadi, Jian Tang, David J Gordon, Daniel A Harki, Peter M Gordon
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. Bioconjugate chemistry 29 (4) (2018)
Maksim V Kvach, Fareeda M Barzak, Stefan Harjes, Henry A M Schares, Geoffrey B Jameson, Alex M Ayoub, Ramkumar Moorthy, Hideki Aihara, Reuben S Harris, Vyacheslav V Filichev, Daniel A Harki, Elena Harjes
Inhibiting APOBEC3 Activity with Single-Stranded DNA Containing 2'-Deoxyzebularine Analogues. Biochemistry 58 (5) (2018)
Jeffrey R Wagner, Özlem Demir, Michael A Carpenter, Hideki Aihara, Daniel A Harki, Reuben S Harris, Rommie Elizabeth Amaro
Determinants of Oligonucleotide Selectivity of APOBEC3B. Journal of chemical information and modeling 59 (5) (2018)
Anand Divakaran, Siva K Talluri, Alex M Ayoub, Neeraj K Mishra, Huarui Cui, John C Widen, Norbert Berndt, Jin-Yi Zhu, Angela S Carlson, Joseph J Topczewski, Ernst K Schonbrunn, Daniel A Harki, William C K Pomerantz
Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. Journal of medicinal chemistry 61 (20) (2018)
John C Widen, Aaron M Kempema, Jordan W Baur, Hannah M Skopec, Jacob T Edwards, Tenley J Brown, Dennis A Brown, Frederick A Meece, Daniel A Harki
Helenalin Analogues Targeting NF-κB p65: Thiol Reactivity and Cellular Potency Studies of Varied Electrophiles. ChemMedChem 13 (4) (2018)
John C Widen, Aaron M Kempema, Peter W Villalta, Daniel A Harki
Targeting NF-κB p65 with a Helenalin Inspired Bis-electrophile. ACS chemical biology 12 (1) (2016)
Paul A Jackson, John C Widen, Daniel A Harki, Kay M Brummond
Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions. Journal of medicinal chemistry 60 (3) (2016)

Daniel A Harki.css-eqlu8i{font-size:small;padding-left:4px;} (Daniel Harki)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel A Harki (Daniel Harki)